Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Luminex and ViroNovative have signed a licensing agreement that gives Luminex worldwide rights to use ViroNovative's human metapneumovirus intellectual property in the xTAG respiratory viral panel.
Subscribe to our email newsletter
Under the terms of the agreement, rights to ViroNovative’s human metapneumovirus (hMPV) intellectual property will be extended to Luminex’s distributors and end-user customers around the world.
Luminex’s xTAG respiratory viral panel (RVP) has received 510(k) clearance from the FDA earlier 2008. The test was cleared for the detection and identification of 12 viruses and viral subtypes that are together responsible for more than 85% of respiratory viral infections.
xTAG RVP is said to be the first multiplexed nucleic acid test for respiratory viruses cleared for in vitro diagnostic use by the FDA and is the first and only test cleared by FDA for the detection of hMPV.
Jeremy Bridge-Cook, vice president of molecular diagnostics at Luminex, said: “Having this license as part of our xTAG RVP assay is important to us as it allows our customers to use this cutting-edge test without the need to individually secure rights to this intellectual property.”